Identification of HLA class I-binding peptides derived from unique cancer-associated proteins by mass spectrometric analysis.

BACKGROUND/AIM Since antigenic peptides of the cancer-associated antigens presented on human leukocyte antigen (HLA) molecules are recognized by specific cytotoxic T-lymphocytes, they have the potential to becoming effective peptide vaccines for cancer immunotherapy. MATERIALS AND METHODS Peptides binding to HLA-A*0201 and HLA-A*2402 obtained from human prostate cancer cells by acid-elution were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and source proteins of the peptides were determined based on the HLA-binding capacity listed on the Syfpeithi. RESULTS We identified TKLSA possibly derived from absent in melanoma 1-like protein (AIM1L), and RLRYT from trans-membrane protein-191C (TMEM 191C) or c20orf201. Messenger RNAs encoding these proteins were expressed in various cancer cell types but none or very few in non-cancerous tissues except for testis, cerebellum and ovary. CONCLUSION HLA class I-binding peptides of unique cancer-associated proteins were identified by MS analysis, and might become a promising tool for the generation of novel cancer vaccines.

[1]  D. Meek,et al.  MAGE-A antigens as targets in tumour therapy. , 2012, Cancer letters.

[2]  O. Kallioniemi,et al.  High-Throughput Transcriptomic and RNAi Analysis Identifies AIM1, ERGIC1, TMED3 and TPX2 as Potential Drug Targets in Prostate Cancer , 2012, PloS one.

[3]  T. Daemen,et al.  From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors , 2011, Clinical & developmental immunology.

[4]  E. K. Jagusztyn-Krynicka,et al.  Proteomics for development of vaccine. , 2011, Journal of proteomics.

[5]  M. Disis,et al.  Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. , 2011, Omics : a journal of integrative biology.

[6]  C. Cheng,et al.  Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis , 2011, Spermatogenesis.

[7]  F. Marincola,et al.  Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells , 2011, Proteomics.

[8]  H. Lyerly,et al.  MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. , 2011, Journal of proteomics.

[9]  K. Blackwell,et al.  MHC Class I–Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer , 2011, Clinical Cancer Research.

[10]  M. Smyth,et al.  Improving cancer immunotherapy by targeting tumor-induced immune suppression , 2011, Cancer and Metastasis Reviews.

[11]  Franck Pagès,et al.  Tumor immunosurveillance in human cancers , 2011, Cancer and Metastasis Reviews.

[12]  T. K. Maiti,et al.  Tumour escape mechanisms and their therapeutic implications in combination tumour therapy , 2010, Cell biology international.

[13]  J. Galon,et al.  Natural immunity to cancer in humans. , 2010, Current opinion in immunology.

[14]  J. Schlom,et al.  Vaccines against Human Carcinomas: Strategies to Improve Antitumor Immune Responses , 2010, Journal of biomedicine & biotechnology.

[15]  N. Sato,et al.  Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer , 2009, Journal of Translational Medicine.

[16]  S. Mocellin,et al.  Peptide-based anticancer vaccines: recent advances and future perspectives. , 2009, Current medicinal chemistry.

[17]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[18]  H. Tajiri,et al.  Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti‐tumour immunity , 2009, Clinical and experimental immunology.

[19]  G. Ball,et al.  Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective. , 2007, Vaccine.

[20]  L. Zitvogel,et al.  Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells. , 2007, Cancer genomics & proteomics.

[21]  L. Karns,et al.  Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. , 2003, International immunology.

[22]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Yao-Tseng Chen,et al.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy , 2002, Immunological reviews.

[24]  A. Gambotto,et al.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Yan A. Su,et al.  AIM1, a novel non-lens member of the βγ-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma , 1997 .

[26]  P. Meltzer,et al.  Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma. , 1996, Oncogene.

[27]  Yana Zhang,et al.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use. , 2012, American journal of blood research.

[28]  G. Berchem,et al.  Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? , 2010, Tissue antigens.

[29]  Yao-Tseng Chen,et al.  NY-ESO-1: review of an immunogenic tumor antigen. , 2006, Advances in cancer research.

[30]  P. Meltzer,et al.  AIM1, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.